The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Celgene; Lilly; MSD; Novartis; Pfizer; Roche; Seagen; SOMATEX
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Lilly; MSD; Novartis; Pfizer; Roche; Seagen; SOMATEX
 
Honoraria - Amgen; AstraZeneca; Celgene; Clovis Oncology; CureVac; Eisai; Genomic Health; GlaxoSmithKline; Immunomedics; Janssen-Cilag; Lilly; MSD; Novartis; Pfizer; PharmaMar; Roche; Seagen; Tesaro
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
 
Frederik Marmé
No Relationships to Disclose
 
Elmar Stickeler
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche; Tesaro
 
Jenny Furlanetto
No Relationships to Disclose
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Honoraria - Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Merck; Molecular Health; MSD Oncology
Research Funding - Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software
Travel, Accommodations, Expenses - Roche
 
Marcus Schmidt
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AMGEN; AstraZeneca; Eisai; Lilly; MSD Oncology; Myelo Therapeutics GmbH; Novartis; Pantarhei Bioscience; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); BioNTech (Inst); Genentech/Roche (Inst); Myelo Therapeutics GmbH (Inst); Pantarhei Bioscience (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - EP 2390370 B1 A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent; EP 2951317 B1 METHOD FOR PREDICTING THE BENEFIT FROM INCLUSION OF TAXANE IN A CHEMOTHERAPY REGIMEN IN PATIENTS WITH BREAST CANCER
Travel, Accommodations, Expenses - Pfizer; Roche
 
Mattea Reinisch
No Relationships to Disclose
 
Toralf Reimer
Honoraria - Lilly; Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer
 
Wolfgang Janni
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; Seagen
Research Funding - Amgen (Inst); Janssen Diagnostics; Lilly (Inst); Menarini Silicon Biosystems; Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Michael Untch
Honoraria - Agendia (Inst); Art tempi (Inst); AstraZeneca (Inst); Bristol Myer Squibb (Inst); Celgene (Inst); Daiji Sankyo (Inst); MSD Oncology (Inst); Mundipharma (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Abbvie (Inst); Agendia (Inst); Amgen (Inst); Celgene (Inst); Lilly (Inst); MSD Oncology (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Seagen (Inst)
 
Bruno Valentin Sinn
Travel, Accommodations, Expenses - HTG Molecular Diagnostics
 
Volker Moebus
Consulting or Advisory Role - Amgen; Myelo Therapeutics GmbH; Roche; Tesaro
Speakers' Bureau - Amgen; AstraZeneca; Celgene; Roche; Teva
 
Laura Michel
Honoraria - AstraZeneca; Eisai; Lilly; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Pfizer; Roche
 
Laura Schoellhorn
No Relationships to Disclose
 
Sabine Schmatloch
No Relationships to Disclose
 
Julia Rey
No Relationships to Disclose
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Samsung (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)